Companies / Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc.
Nasdaq: KLRSCIK 1754068BERKELEY HEIGHTS, NJ
Insider flow · last 90 daysNet buys $1.18M
Financials · FY2020
Ownership
23.8M shares outstanding · as of Aug 4, 2026
Ownership
| Insiders | 54.26% | 12,915,520 |
| Institutions | 75.96% | 18,081,301 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 11
View all →| Insider | % of shares | Shares |
|---|---|---|
Akkaraju SrinivasDirector · 10% owner | 54.26% | 12,915,520 |
Hagen Brett RChief Accounting Officer | 0.00% | 0 |
Adamis Anthony PDirector | — | — |
Feinsod MatthewChief Medical Officer | — | — |
Gall MatthewChief Financial Officer | — | — |
Oxtoby AndrewSee Remarks · Director | — | — |
Patterson Leone DDirector | — | — |
Samsara BioCapital GP, LLC10% owner | — | — |
Samsara BioCapital, L.P.10% owner | — | — |
Samsara Opportunity Fund GP, LLC10% owner | — | — |
Institutional holders 55
View all →| Holder | Value | % of shares |
|---|---|---|
| $109.28M | 54.39% | |
| $10.97M | 5.46% | |
| $5.91M | 2.94% | |
| $3.68M | 1.83% | |
| $3.40M | 1.70% | |
| $3.04M | 1.51% | |
| $2.47M | 1.23% | |
| $1.18M | 0.59% | |
| $844.0K | 0.42% | |
| $844.0K | 0.42% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Millennium Management LLC 13F manager | New | Common Stock | $343.5K | +60K | 59,534 0.25% of shares | low |
| Q1 2026 as of | OMERS Administration Corporation 13F manager | Exit | Common Stock | $-253.2K | -30K -100.00% | 0 | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Trim | Common Stock | $-124.6K | -22K -24.62% | 66,151 0.28% of shares | low |
| Q1 2026 as of | Keel Point, LLC 13F manager | Exit | Common Stock | $-86.3K | -10K -100.00% | 0 | low |
| Q2 2026 as of | Quadrature Capital Ltd 13F manager | New | Common Stock | $67.3K | +17K | 16,527 0.07% of shares | low |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common Stock | $65.1K | +16K +41.58% | 54,442 0.23% of shares | low |
| Q4 2025 as of | Bank of America Corp /De 13F manager | Add | Common Stock | $54.8K | +6K +2989.40% | 6,704 0.03% of shares | low |
| Q4 2025 as of | Barclays PLC 13F manager | New | Common Stock | $51.2K | +6K | 6,065 0.03% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| RTW Investments, LP | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| KLRS | Common Stock | 482929106 |